Stocks · News reference
Icecure Medical (NASDAQ:ICCM) reported quarterly losses of $(1.37) per share which beat the analyst consensus estimate of $(1.40) by 2.14 percent. This is a 23.89 percent increase over losses of $(1.80) per share from
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Adds Legacy Health in Portland, Oregon, with its Legacy Medical Group–Surgical Oncology at Good Samaritan Medical Center , as a new U.S. clinical site for its post-marketing study (the "ChoICE Study") evaluating
Icecure Medical (NASDAQ:ICCM) released second-quarter financial results and hosted an earnings call on Wednesday. Read the complete transcript below. This content is powered by Benzinga APIs. For comprehensive financial
IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to